Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review-Reference-Cited by-同舟云学术

Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review

Published:2022-04-16 Issue:5 Volume:63 Page:1242-1245
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lo Andrea C.¹²³^ORCID,Holloway Caroline L.²³⁴^ORCID,Savage Kerry J.³⁵⁶^ORCID,Sehn Laurie H.³⁵⁶^ORCID,Worsley Daniel F.⁷,Connors Joseph M.³⁵⁶^ORCID,Pickles Tom¹²³^ORCID

Affiliation:

1. Department of Radiation Oncology, British Columbia Cancer Vancouver, Vancouver, Canada

2. Department of Surgery, University of British Columbia (UBC), Vancouver, Canada

3. BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada

4. Department of Radiation Oncology, British Columbia Cancer Victoria, Victoria, Canada

5. Department of Medical Oncology, British Columbia Cancer, Vancouver, Canada

6. Department of Medicine, University of British Columbia (UBC), Vancouver, Canada

7. Department of Nuclear Medicine, Vancouver General Hospital, Vancouver, Canada

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2060505

Reference14 articles.

1. Ocular Adnexal Lymphomas: A Review

2. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma

3. Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

4. 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

5. Holloway C, Pickles T, Croteau N, et al. Treatment outcomes of low grade lymphoma of the orbit. Clin Oncol. 2022.